Integra LifeSciences reports Q3 2022 GAAP EPS $0.60, adjusted EPS $0.86; raises FY adjusted EPS guidance

INTEGRA LIFESCIENCES HOLDINGS CORP

2022-Q3 EPS reported $1.53 revenue$1,159,644,000

Q3 revenues $385M (-0.4% reported, +3.5% organic); GAAP EPS $0.60 (vs $0.51), adjusted EPS $0.86 (flat YoY).
Codman Specialty Surgical rev $249.8M (-2.6% reported, +1.6% organic); Tissue Technologies rev $135.4M (+3.9% reported, +7.2% organic).
Raised FY2022 adjusted EPS guidance to $3.29-$3.33; reaffirmed rev $1,551M-$1,563M with organic growth 3.7%-4.5%.
Completed TWC divestiture to Gentell for $28.8M ($27.8M cash + $1M contingent consideration).
CereLink recall provision $1.5M, rework $0.8M; return-to-market expected 1H2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.